Literature DB >> 20045923

[Preparation and preliminary evaluation of KGDS-targeted ultrasound contrast agent].

Feng Gao1, Yanfei Ding, Xiaoxi Sheng, Wei Wang, Qi Liang, Zhuoqiong Luo, Ping Zhou, Hui Li.   

Abstract

OBJECTIVE: To prepare a thrombus-targeted ultrasonic contrast agent and to investigate its targeted ability to fresh blood clots.
METHODS: We first synthesized FITC-KGDS-Palm compound, and then prepared thrombus-targeted microbubbles using "ultrasound & high speed shearing method". Fluorescence labeling thrombus-specific peptides and KGDS, directed at the activated glycoprotein(GP)IIb/IIIa receptor of platelets were attached to the surface of lipid microbubbles. The concentration and size of TUCA were measured by Malvern Zeta Sizer Nano-ZS590 and Coulter counter. Immunofluorescence was applied to confirm the conjugation. The conjunct ratio was assessed by flow cytometer (FCM).
RESULTS: The KGDS-TUCA was straw yellow turbid liquor, and the concentration was 1.5 x 10(9)/mL, and the average size was 1.5 microm. The targeted microbubbles conjugated with the thrombus-specific peptides showed bright green rings by fluorescence microscope. FCM demonstrated that the wavelength of shell of KGDS-TUCA changed greatly, and the conjunct ratio was 90.04%. In vitro study showed KGDS-TUCA remained stable for 48 h at 4 degree C and target-attached to blood clots and showed good stability.
CONCLUSION: The ultrasound & high speed shearing method to prepare TUCA is easy and in favor of purification. KGDS-TUCA has high specific biological activity. The conjunct ratio and stability of KGDS-TUCA are excellent.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20045923

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  1 in total

1.  Effects of Cationic Microbubble Carrying CD/TK Double Suicide Gene and αVβ3 Integrin Antibody in Human Hepatocellular Carcinoma HepG2 Cells.

Authors:  Jiale Li; Ping Zhou; Lan Li; Yan Zhang; Yang Shao; Li Tang; Shuangming Tian
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.